Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18-month-old children.
A booster dose of Haemophilus influenzae type b conjugate vaccine in the second year of life is the final step in the recommended series of doses to protect infants from invasive infection. This study assessed the safety and immunogenicity of PRP-T conjugate vaccine booster doses (Act-HIB, Connaught Laboratories Ltd). The participants were 367 healthy children who had taken part in a study of primary immunization with PRP-T. At 18-19 months old, subjects were randomly assigned to receive diphtheria-pertussis-tetanus (DPT) and PRP-T vaccines either mixed in one syringe (n = 183) or separately in opposite limbs (n = 184). Adverse events were monitored for 48 h after immunization. Blood was obtained prior to vaccination in half of the subjects (combined injections group) and following vaccination in all subjects to test for antibodies to each of the antigens administered. Local adverse reactions were infrequent with PRP-T alone and equally frequent at sites of DPT or DPT/PRP-T injection, except for redness > or = 25 mm in diameter which was more frequent after the combined vaccines (25.1 versus 14.1%, p < 0.01). Systemic adverse events did not differ in type or frequency between groups. Before immunization, the geometric mean anti-PRP level in those tested was 0.41 micrograms ml-1; 26.7% had levels below 0.15 micrograms ml-1. Both treatment groups responded strongly to vaccination. In those serially tested, anti-PRP levels rose by over 90-fold, to 38.1 micrograms ml-1.(ABSTRACT TRUNCATED AT 250 WORDS)
Scheifele
D W
DW
Vaccine Evaluation Center, BC's Children's Hospital, Vancouver, Canada.
Meekison
W
W
Guasparini
R
R
Roberts
A
A
Barreto
L
L
Thipphawong
J
J
Wiltsey
S
S
D005069:Evaluation Studies as Topic; D018073:Haemophilus Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007117:Immunization, Secondary / Q000009:adverse effects*; D007223:Infant; D013745:Tetanus Toxoid / Q000627:therapeutic use*; D018074:Vaccines, Conjugate
D018073:Haemophilus Vaccines; D013745:Tetanus Toxoid; D018074:Vaccines, Conjugate